Pharmaceutical Industry Adopting Lifecycle Models for Process Validation
This article was originally published in The Gold Sheet
Executive Summary
The pharmaceutical industry is incorporating the lifecycle approach to process validation – and seeing some of its benefits after initial misgivings – while an FDA official discussed the elements of a robust process validation program and consequences when these are not in place. Industry is developing separate guidance on designing process validation studies for biotechnological drugs.